Skip Navigation LinksHome > December 1, 2013 - Volume 64 - Issue 4 > Impact of Autologous Dendritic Cell–Based Immunotherapy (AGS...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e3182a4b9ad
Brief Report: Basic and Translational Science

Impact of Autologous Dendritic Cell–Based Immunotherapy (AGS-004) on B- and T-Cell Subset Changes and Immune Activation in HIV-Infected Patients Receiving Antiretroviral Therapy

Jenabian, Mohammad-Ali DVM, PhD*; Nicolette, Charles A. PhD; Tcherepanova, Irina Y. PhD; DeBenedette, Mark A. PhD; Gilmore, Norbert MD, PhD*; Routy, Jean-Pierre MD*,‡

Collapse Box


Abstract: We previously reported that a combination of antiretroviral therapy with 4 monthly injections of each patient's own autologous dendritic cells (AGS-004) electroporated with CD40 ligand and with HIV RNA antigens obtained from each patient's own pre-antiretroviral therapy plasma induced HIV-specific CD8 T-cell responses in 10 patients. To assess other AGS-004–induced immune changes, we evaluated the modifications in B- and T-cell subsets and the level of immune activation in these patients. The proportion of Bm1 naive cells was increased along with an augmentation of the proliferation marker Ki67. Memory B-cell frequency, CD4 and CD8 T-cell subsets, regulatory T-cell frequency, and CD38/HLA-DR/PD-1 T-cell activation levels remained unchanged after AGS-004 dendritic cell immunotherapy.

© 2013 by Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.